Stage increase in lung cancer more frequent after open vs. closed thoracic surgery

January 11, 2016

DENVER - An increase in the stage of non-small cell lung cancer (NSCLC) due to cancer positive lymph node (LN) discovery was more common following open chest surgery for lung lobe removal of early stage lung cancer compared to the closed chest procedure known as video assisted thoracic surgery (VATS).

The standard and often most effective treatment for early stage lung cancer is surgical removal of the tumor and a portion of the lung, with the open thoracotomy the traditional method of choice. Thoracotomies do pose some risk, especially in lung cancer patients with other health problems. VATS is a less invasive approach that has fewer complications, less pain, improved lung function, shorter recovery periods, and lower acute care costs. However, incomplete LN staging by VATS could compromise survival by leaving residual cancer and altering optimal post-surgical treatment because of inaccurate understaging.

The National Cancer Data Base, an oncology outcomes database maintained by the American Cancer Society and the American College of Surgeons with 30 million historical records, was examined for NSCLC patients who underwent lobectomy between 2010 and 2011 for tumors smaller than 7 cm and no apparent LN involvement prior to surgery. Statistical analyses were performed to compare nodal upstaging in VATS compared to open thoracotomies and to determine if there were differences depending on surgical center. By definition, community cancer programs treat 100 to 500 cancer cases per year, comprehensive community cancer programs more than 500 cases, and academic or research programs more than 500 cases in addition to providing postgraduate medical education.

The results published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer, show a total of 16,983 lobectomies were performed; 29.1% using VATS. Of all 4,935 VATS, 4.9% were performed at community centers, 50% at comprehensive community cancer programs, and 45.1% at academic or research centers. Upstaging because of the discovery of cancer in LN during surgery was more frequent in the open vs. closed group (12.8% vs. 10.3%; p<0.001), even though a greater number of LNs (?9 LNs, 43.7% vs. 38.8%; p<0.001) were sampled using VATS. The open approach resulted in longer length of hospital stay (mean 7.4 versus 6.1 days, p<0.001), and a higher 30-day mortality rate (2.1% vs. 1.3%; p<0.001), whereas VATS was more likely to lead to an unplanned 30-day readmission (6.9% vs. 5.9%; p=0.014). For patients who were treated in an academic or research facility, the difference in nodal upstaging for open lobectomy versus VATS was no longer statistically significant (12.2% vs 10.5%; p=0.08; n=2008 per group), but was numerically higher.

The authors suggest that, "Nodal upstaging appears to be affected by facility type, which may represent a surrogate for expertise in minimally invasive surgical procedures." For the future, the authors note, "Standardized quality assurance of lymph node staging during VATS lobectomy is needed to achieve the goal of eliminating differences in staging and there needs to be an analysis of differences in long-term survival rates between VATS and open thoracotomy for lobectomy to ensure that minimally invasive approaches provide tumor control equivalent to that provided by open approaches."
-end-
About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 4,500 lung cancer specialists in over 90 countries. Visit http://www.iaslc.org for more information.

International Association for the Study of Lung Cancer

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.